Press Releases

Clinical Trial Kits Market to Reach US$ 5.1 Bn by 2030

The global Clinical Trial Kits market size is expected to reach USD 5.1 billion by 2030 and is expected to expand at a CAGR of 12.5% from 2021 to 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38471

Growth Factors

The factors driving market expansion include globalization of clinical trials, increasing demand for remote services, and rising clinical trial complexity.

Remote  services are becoming increasingly essential in terms of patient retention, satisfaction, and safety. To enhance their capabilities, pharmaceutical companies have created a relationship with global logistics partners to provide direct-to-patient services. These services provide participants with the flexibility and convenience of participating in the trials while remaining at home.

COVID-19 pandemic has affected the market which resulted in slowing down the trial process. The COVID-19 pandemic is rapidly boosting advances in medical practices that allow people to connect with the healthcare system remotely. This effort of examining the patients at their homes has raised interest in at-home sample collection and testing. Such services offer convenience and minimize potential exposure to SARS-CoV-2. 

Report Highlights

The logistics segment dominated the market for clinical trial kits and accounted for the largest revenue share of 64.9% in 2020. Clinical trial size continues to grow, causing a rippling effect on pharmaceutical packaging. Secondary package design is becoming more important in order to reduce the risk of product damage or activation during transportation. As authorities push the pharmaceutical sector to examine a bigger number of people, studies are growing bigger.

The phase III segment dominated the market for clinical trial kits and accounted for the largest revenue share of 63.3% in 2020 and is likely to remain dominant in the coming future. The major factor that influences the market for phase III is the purpose of testing pharmaceutical products in humans to validate the therapeutic efficacy observed in Phase II on a large number of patients with a specific disease. This is the transition period from chemical to drug state. Many phase II clinical trials concluding with a successful outcome do not survive in phase III, frequently owing to significant side effects of therapeutic efficacy, thus it is important to undertake wider studies.

North America dominated the clinical trial kits market and accounted for the largest revenue share of 51.1% in 2020. Most pharmaceutical businesses located in the U.S. perform the majority of their business in this region. Favorable government efforts and the existence of a large number of companies offering technologically advanced services such as at-home clinical trial services in the U.S. are driving market expansion.

In Asia Pacific, the market for clinical trial kits is projected to witness the fastest CAGR of 12.9% over the forecast period. Asia Pacific has been and continues to be one of the world’s fastest-growing pharmaceutical marketplaces. With more than 60.0% of the world’s population, Asia Pacific has a vast patient pool; the majority remains treatment-naive due to restricted access to inexpensive medical alternatives. Hence, this is likely to generate more demand for related products and services in the region.

Key Players

  • Brooks life science
  • Q2 solutions
  • Patheon (Thermo fisher scientific)
  • LabCorp drug development
  • Charles river laboratories
  • LabConnect
  • Almac group
  • Precision medicine group
  • Cerba research
  • Alpha laboratories
  • Marken
  • Clinigen
Report Coverage Details
Market Size US$ 5.1 billion by 2030
Growth Rate CAGR of 12.5% From 2021 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Service, Phase
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Brooks life science; Q2 solutions; Patheon (Thermo fisher scientific); LabCorp drug development; Charles river laboratories; LabConnect; Almac group; Precision medicine group; Cerba research; Alpha laboratories; Marken; Clinigen

Market Segmentation

  • Service
    • Kitting Solutions
      • Drugs kits
      • Sample collection kits
    • Logistics
      • Transportation
      • Warehousing & Storage
      • Others
  • Phase
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Regional
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East and Africa (MEA)
      • South Africa
      • Saudi Arabia
      • UAE

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38471

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Clinical Trial Kits Market, By Service

7.1.  Clinical Trial Kits Market, by Service, 2021-2030

7.1.1.    Kitting Solutions

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Logistics

7.1.2.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Clinical Trial Kits Market, By Phase

8.1.  Clinical Trial Kits Market, by Phase, 2021-2030

8.1.1.    Phase I

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Phase II

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Phase III

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Phase IV

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Clinical Trial Kits Market, Regional Estimates and Trend Forecast

9.1.  North America

9.1.1.    Market Revenue and Forecast, by Service (2017-2030)

9.1.2.    Market Revenue and Forecast, by Phase (2017-2030)

9.1.3.    U.S.

9.1.3.1.        Market Revenue and Forecast, by Service (2017-2030)

9.1.3.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.1.4.    Rest of North America

9.1.4.1.        Market Revenue and Forecast, by Service (2017-2030)

9.1.4.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.2.  Europe

9.2.1.    Market Revenue and Forecast, by Service (2017-2030)

9.2.2.    Market Revenue and Forecast, by Phase (2017-2030)

9.2.3.    UK

9.2.3.1.        Market Revenue and Forecast, by Service (2017-2030)

9.2.3.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.2.4.    Germany

9.2.4.1.        Market Revenue and Forecast, by Service (2017-2030)

9.2.4.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.2.5.    France

9.2.5.1.        Market Revenue and Forecast, by Service (2017-2030)

9.2.5.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.2.6.    Rest of Europe

9.2.6.1.        Market Revenue and Forecast, by Service (2017-2030)

9.2.6.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.3.  APAC

9.3.1.    Market Revenue and Forecast, by Service (2017-2030)

9.3.2.    Market Revenue and Forecast, by Phase (2017-2030)

9.3.3.    India

9.3.3.1.        Market Revenue and Forecast, by Service (2017-2030)

9.3.3.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.3.4.    China

9.3.4.1.        Market Revenue and Forecast, by Service (2017-2030)

9.3.4.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.3.5.    Japan

9.3.5.1.        Market Revenue and Forecast, by Service (2017-2030)

9.3.5.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.3.6.    Rest of APAC

9.3.6.1.        Market Revenue and Forecast, by Service (2017-2030)

9.3.6.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.4.  MEA

9.4.1.    Market Revenue and Forecast, by Service (2017-2030)

9.4.2.    Market Revenue and Forecast, by Phase (2017-2030)

9.4.3.    GCC

9.4.3.1.        Market Revenue and Forecast, by Service (2017-2030)

9.4.3.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.4.4.    North Africa

9.4.4.1.        Market Revenue and Forecast, by Service (2017-2030)

9.4.4.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.4.5.    South Africa

9.4.5.1.        Market Revenue and Forecast, by Service (2017-2030)

9.4.5.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.4.6.    Rest of MEA

9.4.6.1.        Market Revenue and Forecast, by Service (2017-2030)

9.4.6.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.5.  Latin America

9.5.1.    Market Revenue and Forecast, by Service (2017-2030)

9.5.2.    Market Revenue and Forecast, by Phase (2017-2030)

9.5.3.    Brazil

9.5.3.1.        Market Revenue and Forecast, by Service (2017-2030)

9.5.3.2.        Market Revenue and Forecast, by Phase (2017-2030)

9.5.4.    Rest of LATAM

9.5.4.1.        Market Revenue and Forecast, by Service (2017-2030)

9.5.4.2.        Market Revenue and Forecast, by Phase (2017-2030)

Chapter 10.  Company Profiles

10.1.              Brooks life science

10.1.1.  Company Overview

10.1.2.  Service Offerings

10.1.3.  Financial Performance

10.1.4.  Recent Initiatives

10.2.              Q2 solutions

10.2.1.  Company Overview

10.2.2.  Service Offerings

10.2.3.  Financial Performance

10.2.4.  Recent Initiatives

10.3.              Patheon (Thermo fisher scientific)

10.3.1.  Company Overview

10.3.2.  Service Offerings

10.3.3.  Financial Performance

10.3.4.  Recent Initiatives

10.4.              LabCorp drug development

10.4.1.  Company Overview

10.4.2.  Service Offerings

10.4.3.  Financial Performance

10.4.4.  Recent Initiatives

10.5.              Charles river laboratories

10.5.1.  Company Overview

10.5.2.  Service Offerings

10.5.3.  Financial Performance

10.5.4.  Recent Initiatives

10.6.              LabConnect

10.6.1.  Company Overview

10.6.2.  Service Offerings

10.6.3.  Financial Performance

10.6.4.  Recent Initiatives

10.7.              Almac group

10.7.1.  Company Overview

10.7.2.  Service Offerings

10.7.3.  Financial Performance

10.7.4.  Recent Initiatives

10.8.              Precision medicine group

10.8.1.  Company Overview

10.8.2.  Service Offerings

10.8.3.  Financial Performance

10.8.4.  Recent Initiatives

10.9.              Cerba research

10.9.1.  Company Overview

10.9.2.  Service Offerings

10.9.3.  Financial Performance

10.9.4.  Recent Initiatives

10.10.           Alpha laboratories

10.10.1.               Company Overview

10.10.2.               Service Offerings

10.10.3.               Financial Performance

10.10.4.               Recent Initiatives

10.11.           Marken

10.11.1.               Company Overview

10.11.2.               Service Offerings

10.11.3.               Financial Performance

10.11.4.               Recent Initiatives

10.12.           Clinigen

10.12.1.               Company Overview

10.12.2.               Service Offerings

10.12.3.               Financial Performance

10.12.4.               Recent Initiatives

Chapter 11.  Research Methodology

11.1.              Primary Research

11.2.              Secondary Research

11.3.              Assumptions

Chapter 12.  Appendix

12.1.              About Us

Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38471

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com

 

Show More

Related Articles

Back to top button